次世代型VLPワクチン
研究開発センター

論文

• D'Alessandro-Gabazza CN, Yasuma T, Kobayashi T, Toda M, Abdel-Hamid AM, Fujimoto H, Hataji O, Nakahara H, Takeshita A, Nishihama K, Okano T, Saiki H, Okano Y, Tomaru A, D'Alessandro VF, Shiraishi M, Mizoguchi A, Ono R, Ohtsuka J, Fukumura M, Nosaka T, Mi X, Shukla D, Kataoka K, Kondoh Y, Hirose M, Arai T, Inoue Y, Yano Y, Mackie RI, Cann I, Gabazza EC. Inhibition of lung microbiota-derived proapoptotic peptides ameliorates acute exacerbation of pulmonary fibrosis. Nat Commun 13: 1558, 2022.
• Ohtsuka J, Imai M, Fukumura M, Maeda M, Eguchi A, Ono R, Maemura T, Ito M, Yamayoshi S, Kataoka Y, Kawaoka Y, Nosaka T. Non-propagative human parainfluenza virus type 2 nasal vaccine robustly protects the upper and lower airways against SARS-CoV-2. iScience 24: 103379, 2021.
• Ono R, Masuya M, Inoue N, Shinmei M, Ishii S, Maegawa Y, Mahrjan BD, Katayama N, Nosaka T. Tett1 is not required for myeloid leukemogenesis by MLL-ENL in novel mouse models. PLos ONE 16: e0248425, 2021.
• Sawaki A, Miyazaki K, Yamaguchi M, Takeuchi T, Kobayashi K, Imai H, Tawara I, Ono R, Nosaka T, Katayama N. Genetic polymorphisms and vincristine-induced peripheral neuropathy in patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone therapy. Int J Hematol 111: 686-691, 2020.
• D'Alessandro-Gabazza CN, Kobayashi T, Yasuma T, Toda M, Kim H, Fujimoto H, Hataji O, Takeshita A, Nishihama K, Okano T, Okano Y, Nishii Y, Tomaru A, Fujiwara K, D'Alessandro VF, Abdel-Hamid AM, Ren Y, Pereira GV, Wright CL, Hernandez A, Fields CJ, Yau PM, Wang S, Mizoguchi A, Fukumura M, Ohtsuka J, Nosaka T, Kataoka K, Kondoh Y, Wu J, Kawagishi H, Yano Y, Mackie RI, Cann I, Gabazza EC. A Staphylococcus pro-apoptotic peptide induces acute exacerbation of pulmonary fibrosis. Nat Commun 11:1539, 2020.
• Ohtsuka J, Fukumura M, Furuyama W, Wang S, Hara K, Maeda M, Tsurudome M, Miyamoto H, Kaito A, Tsuda N, Kataoka Y, Mizoguchi A, Takada A, Nosaka T. A versatile platform technology for recombinant vaccines using non-propagative human parainfluenza virus type 2 vector. Sci Rep 9: 12901, 2019.
• Ohtsuka J, Matsumoto Y, Ohta K, Fukumura M, Tsurudome M, Nosaka T, Nishio M. Nucleocytoplasmic shuttling of the human parainfluenza virus type 2 phosphoprotein. Virology 528: 54-63, 2019.
• Maharjan BD, Ono R, Nosaka T. Eya2 is critical for the E2A-HLF-mediated immortalization of mouse hematopoietic stem/progenitor cells. Int J Oncol 54: 981-990, 2019.
• Nagatake T, Suzuki H, Hirata S, Matsumoto N, Wada Y, Morimoto S, Nasu A, Shimojou M, Kawano M, Ogami K, Tsujimura Y, Kuroda E, Iijima N, Hosomi K, Ishii KJ, Nosaka T, Yasutomi Y, Kunisawa J. Immunological association of inducible bronchus-associated lymphoid tissue organogenesis in Ag85B-rHPIV2 vaccine-induced anti-tuberculosis mucosal immune responses in mice. Int Immunol 30: 471-481, 2018.
• Tsurudome M, Ohtsuka J, Ito M, Nishio M, Nosaka T. The hemagglutinin-neuraminidase (HN) head domain and the fusion (F) protein stalk domain of the parainfluenza viruses affect the specificity of the HN-F interaction. Front Microbiol 9: 391, 2018.
• Ono R, Masuya M, Ishii S, Katayama N, Nosaka T. Eya2, a target activated by Plzf, is critical for PLZF-RARA-induced leukemogenesis. Mol Cell Biol 37: e00585-16, 2017.
• Takeuchi T, Yamaguchi M, Kobayashi K, Miyazaki K, Tawara I, Imai H, Ono R, Nosaka T, Tanaka K, Katayama N. MYD88, CD79B, and CARD11 gene mutations in CD5-positive diffuse large B-cell lymphoma. Cancer 123: 1166-1173, 2017.
• Yamanaka K, Nakanishi T, Isono K, Hasegawa C, Inada Y, Mizutani K, Matsushima Y, Okada K, Mabuchi T, Kondo M, Yamagiwa A, Kakeda M, Habe K, Nosaka T, Gabazza EC, Yamazaki H, Mizutani H, Kawano M.　Restrictive interleukin-10 induction by an innocuous Parainfluenza virus vector ameliorates nasal allergy. J Allergy Clin Immunol 139: 682-686.e7, 2017.